

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.- C-273, Sector-63 Noida, Gautam Buddha Nagar, Uttar Pradesh, 201301

Website- www.raymedlab.com

E-mail- raymedlabsltd@gmail.com, Phone no. - 0120-2426900, 9412700300

Date: 06.11.2024

To,
Head Listing Compliance,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Security Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We would like to inform that the Board of Directors in their meeting held today i.e. **Wednesday, November 06, 2024** (commenced at **04:00 P.M.** and concluded at **05:25 P.M.**) has approved inter alia, to consider and take on record the following matters:

1. **Unaudited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and half year ended September 30, 2024. **(Copy enclosed)**
2. **Unaudited Standalone Statement of Assets and Liabilities** as per Regulation 33 (3)(f) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for half year ended September 30, 2024. **(Copy Enclosed)**
3. **Unaudited Cash Flow Statement** as per Regulation 33(3)(g) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for half year ended September 30, 2024. **(Copy enclosed)**
4. **Limited Review Report** of Statutory Auditor on the aforesaid Un-audited Standalone Financial Results as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and half year ended September 30, 2024. **(Copy enclosed)**

Kindly take the above information on your records.

Thanking you,
Yours Sincerely,
For Raymed Labs Limited

Ajai Goyal
Wholetime Director
DIN: 02636418

Place: Noida

Limited Review Report on the Unaudited Quarterly and year-to-date Standalone Financial Results of Raymed Labs Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Raymed Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone Financial Results of **Raymed Labs Limited** ("the Company") for the quarter and half year ended 30th September 2024 ("the statement"). This statement is being submitted to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (Listing Regulations)
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K T P S & Co.
Chartered Accountants
Firm's Registration No. 134942W

CA Anurag Khandelja
Partner
Mem. No. 172909
UDIN: 24172909BKAKRX5228

Place: Mumbai
Date: 06/11/2024

RAYMED LABS LIMITED
CIN: L24111UP1992PLC014240
Reg. off. - C-273, Sector-63 Noida, Gautam Buddha Nagar, Uttar Pradesh, 201301
Website- www.raymedlab.com
E-mail- raymedlabsltd@gmail.com, Phone no. - 0120-2426900, 9412700300

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended September 30, 2024

Particulars	Amt. (In Lakhs)					
	Quarter Ended			Half Year Ended		Year Ended
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	0.00	0.00	0	0	0	0
II. Other Income	0.00	0.00	0	0	0	0
III. Total Income (I +II)	0.00	0.00	0	0	0	0
IV. Expenses						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.80	0.90	0.90	1.70	1.80	3.60
Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.11	0.18	0.09	0.29	0.18	0.48
Other Expenses:	0.74	0.89	0.71	1.43	1.3	6.09
Total Expenses (IV)	1.65	1.77	1.70	3.42	3.28	10.16
V. Profit/(Loss) before exceptional items and tax (III- IV)	0.00	0.00	0.00	0.00	0.00	0.00
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-1.65	-1.77	-1.70	-3.42	-3.28	-10.16
VIII. Tax Expense						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-1.65	-1.77	-1.70	-3.42	-3.28	-10.16
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-1.65	-1.77	-1.70	-3.42	-3.28	-10.16
XIV. Other Comprehensive Income	0.00	0.00	0	0	0	0
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	-1.65	-1.77	-1.70	-3.42	-3.28	-10.16
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)						
XVI. Paid up Equity Share Capital (Face Value of Rs. 10/- Each)	427.35	427.35	427.35	427.35	427.35	427.35
XVII. Other Equity	0.00	0.00	0.00	0.00	0.00	-668.11
Reserves excluding Revaluation Reserves as per balance sheet						
XIX. Earnings per equity share (for continuing operation):						
(1) Basic	-0.04	-0.04	-0.04	-0.04	-0.08	-0.24
(2) Diluted	-0.04	-0.04	-0.04	-0.08	-0.08	-0.24
XX. Earnings per equity share (for discontinued operation):						
(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XX. Earnings per equity share (for discontinued or Continuing operation):						
(1) Basic	-0.04	-0.04	-0.04	-0.08	-0.08	-0.24
(2) Diluted	-0.04	-0.04	-0.04	-0.08	-0.08	-0.24

Notes:

- The above results have been reviewed by Audit Committee meeting held on 06th November 2024 and thereafter approved by the Board of Directors at their meeting held on 06th November 2024.
- The Statutory Auditors have carried out Limited Review of the financial results of the Company for the quarter and half year ended September 30, 2024 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Statutory Auditors have expressed an unmodified opinion on these results.
- The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.
- The above financial results of the Company are available on the Company's website www.raymedlab.com and also at www.bseindia.com

For Raymed Labs Limited

(Ajai Goyal)
Whole-Time Director
DIN : 02636418

Date: 06.11.2024
Place of signing :Noida

Statement of Unaudited Standalone Assets and Liabilities as at September 30, 2024

Particulars	Amount in Lakhs	
	As at Current Half Year Ended	As at Previous Year Ended
	30.09.2024	31.03.2024
	(Unaudited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	14.28	14.58
(b) Capital Work in Progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financials Assets-	0	0
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.00	0.00
(iv) Other(to be specified)	0.00	0.00
(i) Deferred tax assets (net)	0.00	0
(j) Other non-current assets	0.00	0
TOTAL NON CURRENT ASSETS	14.28	14.58
Current Assets		
(a) Inventories	0.00	0.00
(b) Financials Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	0.00	0.00
(iii) Cash and cash equivalents	100.05	0.05
(iv) Bank Balance other than (iii) above	0.00	0.00
(v) Loans	0.45	0.45
(vi) Otheres (to be specified)	0.00	0.00
(c) Current tax Assets		
(i) Investments	0.00	0.00
(d) Other current Assets	0.00	0.00
TOTAL CURRENT ASSETS	100.50	0.50
TOTAL ASSETS	114.78	15.08
EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-671.52	-668.11
Liabilities		
Non -Current liabilities		
(a) Financials Liabilities		
(i) Borrowings	346.16	243.17
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liabilities (other than specified in item (b) to be specified	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deffered Tax Liabilites (net)	0.00	0.00
(d) Other Non-Current Liabilities	0.00	0.00
TOTAL NON CURRENT LIABILITIES	346.16	243.17
Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payables	0.00	0.00
(A) total outstanding dues of micro enterprises and small enterprises		
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	0.00	0.00
(iii) Other Financial liabilities (other than specified in item (c) to be specified	5	5.00
(b) Other current liabilities	7.79	7.66
(c) Provisions	0.00	0.00
(d) Current Tax Liabilities (net)	0.00	0.00
TOTAL CURRENT LIABILITIES	12.81	12.67
TOTAL EQUITY AND LIABILITES	114.78	15.08

For Raymed Labs Limited

Ajai Goyal
Whole Time Director
DIN : 02636418

Date: 06.11.2024
Place of Signing : Noida

RAYMED LABS LIMITED
CIN: L24111UP1992PLC014240
Reg. off.- C-273, Sector-63 Noida, Gautam Buddha Nagar, Uttar Pradesh, 201301
Website- www.raymedlab.com
E-mail- raymedlabsltd@gmail.com, Phone no. - 0120-2426900, 9412700300

UNAUDITED STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2024

<i>Particulars</i>	Amount in Lakhs
	Half year ended
	01-04-2024 to 30-09-2024
	Unaudited
Cash flow from Operating Activities	
Profit Before Tax	-3.42
Adjustments for	
Adjustments for finance costs	0
Adjustments for decrease (increase) in inventories	0
Adjustments for decrease (increase) in trade receivables, current	0
Adjustments for decrease (increase) in trade receivables, non-current	0
Adjustments for decrease (increase) in other current assets	0
Adjustments for other financial assets, non-current	0
Adjustments for other financial assets, current	0
Adjustments for other bank balances	0
Adjustments for increase (decrease) in trade payables, current	0
Adjustments for increase (decrease) in trade payables, non-current	0
Adjustments for increase (decrease) in other current liabilities	0.15
Adjustments for increase (decrease) in other non-current liabilities	0
Adjustments for depreciation and amortisation expense	0.29
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
Adjustments for provisions, current	0
Adjustments for provisions, non-current	0
Adjustments for other financial liabilities, current	0
Adjustments for other financial liabilities, non-current	0
Adjustments for unrealised foreign exchange losses gains	0
Adjustments for dividend income	0
Adjustments for interest income	0
Adjustments for share-based payments	0
Adjustments for fair value losses (gains)	0
Adjustments for undistributed profits of associates	0

Other adjustments for which cash effects are investing or financing cash	0
Other adjustments to reconcile profit (loss)	0
Other adjustments for non-cash items	0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
Total adjustments for reconcile profit (loss)	
Net cash flows from (used in) operations	2.99
Dividends received	0
Interest paid	0
Interest received	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Net cash flows from (used in) operating activities	2.99
Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	0
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
Proceeds from sales of property, plant and equipment	0
Purchase of property, plant and equipment	0
Proceeds from sales of investment property	0
Purchase of investment property	0
Proceeds from sales of intangible assets	0
Purchase of intangible assets	0
Proceeds from sales of intangible assets under development	0
Purchase of intangible assets under development	0
Proceeds from sales of goodwill	0
Purchase of goodwill	0
Proceeds from biological assets other than bearer plants	0
Purchase of biological assets other than bearer plants	0
Proceeds from government grants	0
Proceeds from sales of other long-term assets	0
Cash receipts from repayment of advances and loans made to other parties	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0

Dividends received	0
Interest received	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	102.99
Net cash flows from (used in) investing activities	102.99
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries	0
Payments from changes in ownership interests in subsidiaries	0
Proceeds from issuing shares	0
Proceeds from issuing other equity instruments	0
Payments to acquire or redeem entity's shares	0
Payments of other equity instruments	0
Proceeds from exercise of stock options	0
Proceeds from issuing debentures notes bonds etc	0
Proceeds from borrowings	0
Repayments of borrowings	0
Payments of finance lease liabilities	0
Payments of lease liabilities	0
Dividends paid	0
Interest Paid	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Net cash flows from (used in) financing activities	100
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0
Effect of exchange rate changes on cash and cash equivalents	0
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	100
Cash and cash equivalents cash flow statement at beginning of period	0.05
Cash and cash equivalents cash flow statement at end of period	100.05
For Raymed Labs Limited	
Ajai Goyal Whole Time Director DIN: 02636418	

Date: 06.11.2024

Place of Signing: Noida